NLS Short Long Term Debt Total vs Net Debt Analysis
NLSPW Stock | USD 0.01 0 22.22% |
NLS Pharmaceutics financial indicator trend analysis is infinitely more than just investigating NLS Pharmaceutics recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether NLS Pharmaceutics is a good investment. Please check the relationship between NLS Pharmaceutics Short Long Term Debt Total and its Net Debt accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NLS Pharmaceutics AG. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.
Short Long Term Debt Total vs Net Debt
Short Long Term Debt Total vs Net Debt Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of NLS Pharmaceutics Short Long Term Debt Total account and Net Debt. At this time, the significance of the direction appears to have very strong relationship.
The correlation between NLS Pharmaceutics' Short Long Term Debt Total and Net Debt is 0.84. Overlapping area represents the amount of variation of Short Long Term Debt Total that can explain the historical movement of Net Debt in the same time period over historical financial statements of NLS Pharmaceutics AG, assuming nothing else is changed. The correlation between historical values of NLS Pharmaceutics' Short Long Term Debt Total and Net Debt is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Short Long Term Debt Total of NLS Pharmaceutics AG are associated (or correlated) with its Net Debt. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Debt has no effect on the direction of Short Long Term Debt Total i.e., NLS Pharmaceutics' Short Long Term Debt Total and Net Debt go up and down completely randomly.
Correlation Coefficient | 0.84 |
Relationship Direction | Positive |
Relationship Strength | Strong |
Short Long Term Debt Total
Net Debt
The total debt of a company minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds.Most indicators from NLS Pharmaceutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into NLS Pharmaceutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NLS Pharmaceutics AG. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. At this time, NLS Pharmaceutics' Selling General Administrative is fairly stable compared to the past year. Enterprise Value is likely to climb to about 1.1 B in 2024, whereas Issuance Of Capital Stock is likely to drop 0.00 in 2024.
NLS Pharmaceutics fundamental ratios Correlations
Click cells to compare fundamentals
NLS Pharmaceutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
NLS Pharmaceutics fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 696.4K | 1.2M | 5.8M | 9.3M | 1.8M | 3.3M | |
Short Long Term Debt Total | 7.1M | 842.1K | 2.1M | 1.6M | 1.5M | 1.4M | |
Other Current Liab | 835.7K | 1.4M | 666.4K | 986.4K | 1.7M | 1.0M | |
Total Current Liabilities | 4.0M | 7.2M | 2.4M | 3.4M | 7.9M | 4.5M | |
Total Stockholder Equity | (6.2M) | (9.0M) | 542.4K | 3.3M | (8.8M) | (9.3M) | |
Net Debt | 621.9K | 2.0M | (5.4M) | (8.9M) | 736.1K | 772.9K | |
Retained Earnings | (26.9M) | (29.8M) | (41.7M) | (58.2M) | (70.4M) | (66.9M) | |
Accounts Payable | 2.5M | 4.0M | 1.7M | 2.4M | 4.6M | 2.7M | |
Cash | 220.3K | 93.7K | 5.4M | 8.9M | 897.7K | 852.8K | |
Non Current Assets Total | 314.7K | 1.0M | 41.6K | 30.2K | 23.6K | 22.4K | |
Non Currrent Assets Other | 260.2K | 946.9K | 12.0K | 12.1K | 16.9K | 16.0K | |
Cash And Short Term Investments | 220.3K | 93.7K | 5.4M | 8.9M | 897.7K | 852.8K | |
Common Stock Shares Outstanding | 11.1M | 4.8M | 14.7M | 19.7M | 38.2M | 40.1M | |
Liabilities And Stockholders Equity | 696.4K | 1.2M | 5.8M | 9.3M | 1.8M | 3.3M | |
Non Current Liabilities Total | 2.8M | 3.0M | 2.8M | 2.6M | 2.8M | 3.4M | |
Other Current Assets | 86.1K | 14.4K | 292.0K | 191.0K | 914.7K | 960.5K | |
Other Stockholder Equity | 20.6M | 20.6M | 42.1M | 60.9M | 61.0M | 35.5M | |
Total Liab | 6.9M | 10.2M | 5.2M | 6.0M | 10.7M | 6.6M | |
Net Invested Capital | (5.3M) | (6.9M) | 542.4K | 3.3M | (7.2M) | (6.8M) | |
Total Current Assets | 381.7K | 196.7K | 5.7M | 9.2M | 1.8M | 3.1M | |
Accumulated Other Comprehensive Income | (18.7K) | (19.4K) | (151.7K) | (50.8K) | (158.1K) | (150.2K) | |
Net Working Capital | (3.7M) | (7.0M) | 3.3M | 5.9M | (6.1M) | (5.8M) | |
Net Receivables | 75.4K | 61.2K | 38.6K | 41.2K | 10.7K | 10.1K | |
Inventory | (33.6K) | (61.2K) | (38.6K) | (41.2K) | (37.1K) | (39.0K) | |
Short Term Debt | 690.1K | 1.8M | 2.5B | 1.6M | 1.9M | 1.8M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for NLS Stock Analysis
When running NLS Pharmaceutics' price analysis, check to measure NLS Pharmaceutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NLS Pharmaceutics is operating at the current time. Most of NLS Pharmaceutics' value examination focuses on studying past and present price action to predict the probability of NLS Pharmaceutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NLS Pharmaceutics' price. Additionally, you may evaluate how the addition of NLS Pharmaceutics to your portfolios can decrease your overall portfolio volatility.